Latent autoimmune diabetes in adults (LADA)

LADA is a slowly progressive, autoimmune form of diabetes with adult onset that shares features of type 1 and type 2 diabetes and often leads to insulin dependence.

Author: Leandro Alegsa Creation date: November 13, 2022 Last updated: May 23, 2026

Overview

Latent autoimmune diabetes in adults (LADA) is a form of diabetes that combines elements of both type 1 diabetes and type 2 diabetes. It is an autoimmune condition: the body's immune system, here acting abnormally, attacks insulin-producing tissue in the pancreas. Because it develops in adults and often progresses more slowly than classic childhood-onset type 1, LADA may be overlooked or misdiagnosed at first.

Causes and diagnosis

LADA results from autoimmune destruction of pancreatic beta cells that make insulin. Typical laboratory clues include the presence of autoantibodies (commonly anti-GAD) and a falling C‑peptide level over time. Clinicians may look for autoimmune markers to distinguish LADA from other types of diabetes because clinical presentation alone can be ambiguous.

Clinical features and course

Patients with LADA are usually adults at diagnosis and frequently have a lean or normal body habitus, though some are overweight. Early in the course they may show some degree of insulin resistance, which adds overlap with type 2 diabetes. Unlike rapid-onset type 1 disease, progression to absolute insulin deficiency is typically slower, but many people eventually require insulin therapy.

Management

Treatment aims to maintain blood glucose control and preserve remaining beta-cell function for as long as possible. Typical approaches include:

Early insulin therapy: often recommended to replace lost insulin and reduce demand on remaining beta cells.
Glucose monitoring and lifestyle: diet, exercise, and regular monitoring are important—as they are in other forms of diabetes.
Oral agents: some medications used for type 2 diabetes may be used, but choices should consider autoimmune progression.
Research directions: immunomodulatory therapies have been studied to slow beta-cell loss but are not standard care.

History, prevalence and significance

The term LADA was coined to describe adult-onset autoimmune diabetes that is clinically distinct from classic juvenile type 1. It accounts for a noticeable share of adult diabetes cases and is important because initial misclassification as type 2 can delay appropriate therapy. Awareness of LADA helps clinicians choose tests and treatments tailored to an autoimmune, progressive condition.

Distinguishing points and notable facts

Key points that help differentiate LADA include adult onset, presence of autoantibodies associated with autoimmune disease, gradual beta-cell decline, and variable degrees of insulin resistance. Understanding these differences improves prognosis and treatment planning. For general background on related conditions see immune system discussions and resources about type 1 and type 2 diabetes; for organ-specific context consult materials on the pancreas. Additional clinical guidance and patient information can be found through specialist links and guidelines on beta-cell health and insulin management.

Questions and Answers

Q: What is Latent autoimmune diabetes in adults (LADA)?

A: LADA is a type of diabetes that is similar to both type 1 and type 2 diabetes. It is an autoimmune disease of the pancreas, meaning that the body's immune system attacks the cells in the pancreas that are supposed to make insulin. It also causes insulin resistance, which means that insulin does not work as well as it should in a person's body.

Q: What causes LADA?

A: LADA is caused by an autoimmune response in the body that leads to the destruction of the cells in the pancreas that produce insulin. The exact cause of this autoimmune response is unknown.

Q: How is LADA different from type 1 and type 2 diabetes?

A: LADA is similar to both type 1 and type 2 diabetes. Like type 1 diabetes, it is an autoimmune disease of the pancreas. But like type 2 diabetes, it also causes insulin resistance. Most people with LADA are thin or skinny or have a normal BMI, although some are overweight to slightly obese.

Q: Who is at risk of developing LADA?

A: Anyone can develop LADA, but it is most commonly diagnosed in adults over the age of 30 who are thin or have a normal BMI. People who have a family history of diabetes or other autoimmune diseases may also be at higher risk of developing LADA.

Q: What are the symptoms of LADA?

A: The symptoms of LADA are similar to those of type 1 and type 2 diabetes, including increased thirst, frequent urination, fatigue, blurred vision, and slow-healing sores or cuts. These symptoms may develop gradually over time.

Q: How is LADA diagnosed?

A: LADA is diagnosed through a combination of blood tests and medical history. Doctors may also perform a glucose tolerance test to see how the body responds to a sugary drink. If these tests show that the body is not producing enough insulin or is resistant to insulin, a diagnosis of LADA may be made.

Q: How is LADA treated?

A: The treatment for LADA is similar to the treatment for type 1 and type 2 diabetes, depending on the severity of the condition. This may include lifestyle changes such as diet and exercise, as well as medications such as insulin or oral drugs that help the body use insulin more effectively. Some people with LADA may also benefit from immunosuppressive therapies that help to slow down the autoimmune response in the body.